| INTRODUC TI ON
Despite optimal medical therapy with Angiotensin Converting Enzyme Inhibitors (ACE-I) or Angiotensin Receptor Blockers (ARB), Beta-blockers and Mineralocorticoid Receptor Antagonists (MRA), many heart failure patients with reduced ejection fraction (HFrEF) exhibit a residually depressed cardiac function, paralleled by an increased risk for heart failure hospitalization and cardiovascular mortality. [1] [2] [3] [4] Therapy with an ACE-I, ARB, beta-blocker, and MRA all induce beneficial reverse remodeling in HFrEF patients paralleled by a reduction in heart failure hospitalization and cardiovascular mortality. [5] [6] [7] [8] [9] [10] [11] [12] In the Prospective Comparison of Angiotensin Receptor-
Neprilysin Inhibitor With an Angiotensin-Converting Enzyme
Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, sacubitril/valsartan significantly reduced both heart failure hospitalization and cardiovascular mortality in comparison to guideline recommended doses of enalapril. 13 However, the effect of therapy with sacubitril/valsartan on cardiac function remains unknown. Indeed, it has not been studied if switching therapy from an ACE-I or ARB to sacubitril/valsartan induces incremental reverse remodeling. The current study sought out to determine the effect of sacubitril/valsartan therapy on cardiac function in patients with a current class-I indication for therapy with sacubitril/valsartan. 14 2 | ME THODS
| Study population
The study was a prospective longitudinal assessor blinded study to test the reverse remodeling response to therapy with sacubitril/valsartan. Patients were eligible for the study in accordance to the Belgian reimbursement criteria for sacubitril/valsartan, which consists of (1) symptomatic heart failure defined as New York
Heart Association (NYHA) class II-IV, (2) Left ventricular ejection fraction (LVEF) below 35% measured by echocardiography, (3) pretreatment with an individual optimal dose of ACE-I or ARB for at least 4 weeks. For the latter inclusion criteria, no minimal dose (eg, at least 10 mg of enalapril equivalents) of ACE-I or ARB is defined.
Exclusion criteria for the current study included; (1) or ARB of at least 50% of target dose. Elderly patients, patients on a doses of ACE-I or ARB of less than 50% of target dose, or with a history of liver or kidney insufficiency were initiated on the 24/26 mg dose. Uptitration was performed every 2 weeks if tolerated by the patient. Changes in doses of other neurohormonal blockers, such as beta-blockers and mineralocorticoid receptor antagonists, was not allowed during the study follow-up. All patients provided informed consent to participate in the study.
The study was approved by the local ethical committee and is in accordance to the declaration of Helsinki.
| Data collection and follow-up
Physical examination with registration of NYHA class and echocardiographic evaluation was performed at baseline and followup. Comprehensive 2-dimensional echocardiography exams were performed with a commercially available system (Philips Medical Systems, iE33). Images were acquired in the left lateral decubitus position, triggered to QRS complex and digitally stored in cine loops in digital imaging and communications in medicine (DICOM) format.
Analysis were performed offline by a 2 investigators (H.B. and P.M.)
who were both blinded to the clinical data and timing of the echocardiographic images (not aware which images were baseline vs follow-up). All offline analyses were performed on a dedicated station using TomTec 2D measurements, image arena (TomTec Imaging
Systems GMBH, Unterschleissheim, Germany). All reported echo- was timed between the onset of the E-wave and termination of the A-wave. As DFT is heart rate-dependent, it was indexed (adjusted DFT) by the cycle length (time interval between the onset of 2 consecutive E-waves). Severity of mitral and tricuspid valve regurgitation was assessed in a 4-chamber image using color Doppler imaging, with a visual severity grading from 0 (absent) to 4 (severe).
Right ventricular systolic pressure (RVSP) was measured from a continuous wave Doppler regurgitate tricuspid jet signal if present.
To allow for maximal patient inclusion the timing of the follow-up visit was not prefixed, but coincided with the scheduled follow-up appointment, which was left at the discretion of the treating physicians. However, follow-up had to be between 6 weeks to 6 months after the dose optimization of sacubitril/valsartan, with doses being uptitrated every 2 weeks after initiation. Baseline echocardiography measurement coincided with the initiation of the starting dose of sacubitril/valsartan. All echocardiographic variables measured by the 2 independent blinded investigators were averaged and the inter-observer variability was calculated using the intraclass correlation coefficients.
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| Statistical analysis
Formal power calculation predicted, in order to detect a 3% rise in LVEF with a standard deviation of 6% on the measurement and an α = .05 with a power of 90%, that 44 patients should be enrolled.
Power calculation was performed for LVEF, as this is the most studied 
| RE SULTS

| Baseline population
A total of 141 patients were prospectively included between November 2016 and December 2017. However, 5 patients died and 4 patients discontinued the intake of sacubitril/valsartan before echocardiographic follow-up. Additionally 5 patients were excluded due to insufficient imaging quality and 2 patients were excluded because they underwent CRT placement during followup. Therefore, the final study population constituted of 125 patients. Baseline characteristics are reflected in 
| Reverse remodeling response
All 125 patients had baseline and follow-up echocardiographic evaluation available for paired analysis. The median (IQR) time to follow-up at which echocardiographic reverse remodeling was measured was 118 (77-160) days. The baseline and follow-up echocardiographic analysis are reflected in Table 3 . Some patients treated with a higher dose (97/103 mg) tended to be more often female and more often had a nonischemic etiology of heart failure. As these factors are associated with more reverse remodeling in both CRT literature as in literature regarding heart failure with recovered ejection fraction, multivariate adjustment was performed for these covariates. 18 After adjustment a higher drug-dose independently predicted more improvement in LVEF (P = .001) and more reduction 
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in LVESV (P = .001). In a repeated measure analysis of change in LVEF with treatment dose and treatment duration as fixed covariates, there was also a trend toward more improvement in LVEF in patients treated for a longer duration (P = .053).
Finally, the table S1 illustrates the relationship between changes in NYHA class and echocardiographic parameters, indicating that both improvement in metrics of systolic as well as diastolic function and pulmonary pressures were associated with functional status improvement after the initiation of sacubitril/valsartan. The average inter-observer variability using interclass coefficients was 0.9. In sheep with induced heart failure neprilysin inhibition improves vasodilatory response and natriuresis and diuresis. 22 Furthermore, in mice with myocardial infarction induced heart failure, neprilysin inhibition combined with valsartan resulted in less fibrosis and hypertrophy in comparison to valsartan alone. 23 This resulted in less dilation of LVESV, a more preserved LVEF and a reduction in the Awave velocity. 23 Mechanistically, sacubitril is implicated in attenuating cardiomyocyte cell death, hypertrophy and impaired myocyte contractility. 24 Based on these preclinical and mechanistic evaluations of sacubitril, the incremental beneficial effect on systolic and diastolic function might seem more straightforward.
| D ISCUSS I ON
As with other heart failure therapies, the impact of sacubitril/valsartan on systolic function is most noted on the change in LVESV. 5, 8, 10, 11 After initiation of an ACE-I, ARB, beta-blocker, or MRA the LVESV often drops more than the LVEDV, resulting in an improved LVEF and SV. We found a similar occurrence for sacubitril/valsartan. It is unclear if this is a result of the cellular effects of neprilysin inhibition or is a mere reflection of hemodynamic changes. It is well known that the failing heart is afterload sensitive, although this might be more clinically relevant during episodes of acute heart failure. As in PARADIGM-HF, our patients exhibited a lower systolic blood pressure following initiation of sacubitril/valsartan. 13 This allows the heart to operate at an improved more steeper Frank-Starling relationship.
Furthermore, as other changes in HF therapy were not allowed in our study, the natriuretic and diuretic effects of sacubitril/valsartan could reduce cardiac preload. A reduction in preload allows the failing heart to move away from the flat part of the Frank-Starling curve, hereby beneficially influencing stroke volume. Similarly to MRAs (which also strongly act on the kidney and cardiac fibrosis), sacubitril/valsartan therapy resulted in less patients with a restrictive mitral filling pattern. 5 Additionally, the diastolic filling time improved. Although we did not directly measure the duration of isovolumetric relaxation or isovolumetric contraction, it is conceivable that a reduction in these time intervals (as a reflection of improved systolic and diastolic function) contributes to the longer diastolic filling time. Additionally, we corrected the diastolic filling time for heart rate, excluding a longer diastolic filling time secondary to a slower heart rate. Interestingly, both metrics of systolic and diastolic improvement associated with functional improvement. This might underscore the potential of sacubitril/valsartan therapy in heart failure with preserved ejection fraction (as being studied in the ongoing PARAGON-HF study).
To add further biologic credence to the reverse remodeling effect of sacubitril/valsartan we noted a dose-dependent effect. A similar dose response effect has been noted for other heart failure therapies. 5 It is important to note that patients before initiation were not treated with lower doses of RAS-blockers and given the long duration of heart failure before initiation of sacubitril/valsartan, therapies should be deemed as optimized. Indeed, the dose valsartan after initiation of sacubitril/valsartan was equipotential to the preinitiation dose of ACE-I or ARB. Altogether, our study reliably documents the incremental reverse remodeling potential of sacubitril/valsartan therapy. Additionally, longer treatment with sacubitril/valsartan was associated with a trend toward more reverse remodeling (P = .053). This might suggest that our analysis under-estimates the true reverse remodeling response, which could be even higher with longer follow-up.
Just as in the PARADIGM-HF trial, the proportion of women in our cohort was low. This might be due to several reasons, for instance initiation of sacubitril/valsartan requires a reduced LVEF and toleration of a substantial dose of ACE-I or ARB, which might be more likely to occur in men. 25 Additionally, it is well known that women tend to exhibit a more pronounced reverse remodeling response following initiation of heart failure therapies including pharmacotherapy or CRT. 18 Although cardiologists should be convinced about the compelling benefit of sacubitril/valsartan based on the results of the PARADIGM-HF trial, prescription of sacubitril/valsartan remains rather low. 26 , 27 The underappreciation of the residual risk for morbidity and mortality in the ostensibly stable heart failure patient, the practical hurdles to prescribe and uptitrate of the drug, and perceived incremental costs might all explain the low prescription rate. 26, 27 However, the recognition of an incremental reverse remodeling response to such an effective class-I lifesaving therapy might help to convince more cardiologists about the drug potential.
| Limitations
Several limitations should be addressed. First, this study was not patients will have implantable cardiac devices hampering optimal imaging acquisition for magnetic resonance imaging.
| CON CLUS ION
In heart failure patients with reduced ejection fraction on optimal medical therapy who remain symptomatic, switching from an ACE-I or 
